Market
Percentage reduction in out-of-pocket drug costs for Medicare beneficiaries in 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
21% to 30% • 25%
More than 30% • 25%
Reports from the Centers for Medicare & Medicaid Services (CMS) or other official government health statistics
Story
Medicare Implements $2,000 Annual Cap on Prescription Drug Costs Under Inflation Reduction Act
Dec 31, 2024, 09:50 PM
Starting January 1, Medicare will implement a new annual cap on out-of-pocket prescription drug costs at $2,000 for beneficiaries, a move anticipated to save millions of Americans money on their medications. This cap, part of the Inflation Reduction Act, will apply to drugs purchased at pharmacies or through mail order, offering significant relief to those who require multiple medications. The provision aims to limit the financial burden on Medicare enrollees, who previously faced no limit on out-of-pocket costs for medications covered by their Part D drug plans.
View original story
Similar markets
More than 75% • 25%
50% to 75% • 25%
25% to 50% • 25%
Less than 25% • 25%
$5 billion to $10 billion • 25%
More than $15 billion • 25%
$10 billion to $15 billion • 25%
Less than $5 billion • 25%
More than 90% • 25%
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
Wegovy • 25%
Ozempic • 25%
Other • 25%
Rybelsus • 25%
$10 billion to $15 billion • 25%
$5 billion to $10 billion • 25%
Less than $5 billion • 25%
More than $15 billion • 25%
21-30% • 25%
11-20% • 25%
0-10% • 25%
31% or more • 25%
11-20 drugs • 25%
21-30 drugs • 25%
1-10 drugs • 25%
More than 30 drugs • 25%
10% to 20% • 25%
Less than 10% • 25%
20% to 30% • 25%
More than 30% • 25%
Wegovy • 25%
Other • 25%
Janumet • 25%
Ozempic • 25%
Other • 25%
Insulin • 25%
Cancer drugs • 25%
Cardiovascular drugs • 25%
Ozempic • 25%
Pomalyst • 25%
Wegovy • 25%
Trelegy Ellipta • 25%